Navigation Links
Replidyne to Report 2007 Fourth Quarter and Year-End Earnings
Date:2/5/2008

Presenting at BIO CEO & Investor Conference

LOUISVILLE, Colo., Feb. 5 /PRNewswire-FirstCall/ -- Replidyne, Inc. (Nasdaq: RDYN) announced today that it will host a conference call on Tuesday, February 26, 2008 at 4:45 P.M. ET to report 2007 fourth quarter and year-end earnings. Additionally, Replidyne will present at an upcoming investor conference in February 2008.

Earnings conference call information is as follows:

Kenneth J. Collins, President and CEO, and other members of Replidyne's

senior management team will provide a company update and discuss

earnings results via conference call and webcast on Tuesday, February 26,

2008, at 4:45 P.M. ET. Callers may participate in the conference call by

dialing 866-510-0707 (domestic) or 617-597-5376 (international), and

providing the passcode 33794809. To access the live webcast, please log

on to the company's website at http://www.Replidyne.com and go to the

Investor Relations section.

A replay of the conference call will be available approximately one hour

after completion of the call through Tuesday, March 11, 2008 at midnight.

Callers may access the replay by dialing 888-286-8010 (U.S.

participants) or 617-801-6888 (international participants). The audio

replay passcode is 92464480. To access a replay of the webcast, visit

the Investor Relations section of the company's website at

http://www.Replidyne.com.

Investor conference presentation information is as follows:

-- Mr. Collins will present on Tuesday, February 12, 2008 at 2:45 P.M. ET

at the BIO CEO & Investor Conference, to be held at the Waldorf-Astoria

in New York City. A live audio webcast of this presentation will be

available on the investor relations section of the company's website at

http://www.Replidyne.com. The webcast will be archived and available on

Replidyne's website after the event for a period of 30 days.

-- At the same conference, Replidyne's Chief Commercial Officer Peter

Letendre, Pharm.D. will participate on antibiotics panel "Super Drugs

Against Super Bugs" on Wednesday, February 13, 2008 at 9:30 A.M.

About Replidyne, Inc.

Replidyne is a biopharmaceutical company focused on discovering, developing, in-licensing and commercializing innovative anti-infective products. Replidyne's lead product, faropenem medoxomil, is a novel oral community antibiotic, expected to be appropriate for use as a first-line antibiotic for treatment of respiratory and skin infections in adult and pediatric patients. Replidyne's investigational antibacterial agent REP3123 targets Gram-positive C. difficile bacteria and C. difficile-associated disease (CDAD). Replidyne is pursuing the development of other novel anti-infective programs based on its DNA replication inhibition technology and its in-house discovery research.

Safe Harbor

This press release contains plans, intentions, objectives, estimates and expectations that constitute forward-looking statements about Replidyne, Inc. that involve significant risks and uncertainties. Actual results could differ materially from those discussed due to a number of factors including, the success and timing of pre-clinical studies and clinical trials; the Company's ability to obtain a new partner for faropenem on acceptable terms; the Company's ability to obtain and maintain regulatory approval of product candidates and the labeling under any approval that may be obtained; plans to develop and commercialize product candidates; the loss of key scientific or management personnel; the size and growth of the potential markets for the Company's product candidates and the Company's ability to serve those markets; regulatory developments in the U.S. and foreign countries; the rate and degree of market acceptance of any future products; the accuracy of Company estimates regarding expenses, future revenues and capital requirements; the Company's ability to obtain and maintain intellectual property protection for our product candidates; the successful development of the Company's sales and marketing capabilities; the success of competing drugs that are or become available; and the performance of third party manufacturers. These and additional risks and uncertainties are described more fully in the Company's most recent Form 10-Q filed with the SEC under the Securities Exchange Act of 1934. Copies of filings made with the SEC are available through the SEC's electronic data gather analysis and retrieval system (EDGAR) at http://www.sec.gov. All forward-looking statements made in the press release are made as of the date hereof and the Company assumes no obligation to update the forward-looking statements in the document.


'/>"/>
SOURCE Replidyne, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Replidyne to Announce Third Quarter 2007 Earnings
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. QMed, Inc. Reports July Medicare SNP Enrollments
4. Phlo Affiliate Reports Expanded Coverage to Oregon Border
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Carrington Reports Second Quarter 2007 Results
8. Avitar Reports Third Quarter Financial Results for Fiscal 2007
9. Response Genetics Reports Second Quarter 2007 Financial Results
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Transgenomic, Inc. Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 2017 , ... DuPont Pioneer and recently formed CasZyme, a ... a multiyear collaboration to identify and characterize novel CRISPR-Cas nucleases. The goal of ... across all applications. , Under the terms of the agreement, Pioneer will provide ...
(Date:10/12/2017)... (PRWEB) , ... October 12, ... ... ) has launched Rosalind™, the first-ever genomics analysis platform specifically designed for ... complexity. Named in honor of pioneering researcher Rosalind Franklin, who made a ...
(Date:10/11/2017)... ... , ... ComplianceOnline’s Medical Device Summit is back for its 4th year. The ... Francisco, CA. The Summit brings together current and former FDA office bearers, regulators, industry ... officials from around the world to address key issues in device compliance, quality and ...
(Date:10/11/2017)... ... , ... Disappearing forests and increased emissions are the main causes of the ... Especially those living in larger cities are affected by air pollution related diseases. , ... pollution-affected countries globally - decided to take action. , “I knew I had to ...
Breaking Biology Technology:
(Date:4/13/2017)... UBM,s Advanced Design and Manufacturing event in ... and evolving technology through its 3D Printing and Smart ... the expo portion of the event and feature a ... on trending topics within 3D printing and smart manufacturing. ... will take place June 13-15, 2017 at the Jacob K. ...
(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...
(Date:4/11/2017)... N.Y. , April 11, 2017 ... fingerprints, but researchers at the New York University ... College of Engineering have found that partial similarities ... security systems used in mobile phones and other ... thought. The vulnerability lies in the ...
Breaking Biology News(10 mins):